Almac Discovery Key Research
Ubiquitin Specific Proteases
Deubiquitinating enzymes (DUBs) and their subset ubiquitin specific proteases (USP’s) hold the promise of producing many new drugs across a wide range of indications. Until now this target class has remained intractable, but because of Almac Discovery’s unique knowledge base within this area we are committed to change that.
Antibodies and proteins are a key element of a clinician’s arsenal of therapeutics but they are not perfect. The improvements needed will require notable new technologies. Almac Discovery is exploring drug conjugates as the way forward.
Commercial and Academic Collaborations
Through key commercial and academic collaborations, we look to partner our medicinal chemistry and translational biology expertise with further research capabilities.
Read more on our expert capabilities to know how we can complement your oncology discovery and development research interests.